Lonza to Buy Roche Biologics Manufacturing Site in California for $1.2B 3/20/2024
Clasp Emerges with $150M Series A Financing to Advance T Cell Engagers 3/20/2024
Historic Approval for MASH, CAR-Ts in the Spotlight 3/20/2024
What Another Trump Presidency Could Mean for Big Pharma 3/20/2024
Takeda Reaps Rewards of $5.2B Ariad Bet as FDA Expands Iclusig’s Label 3/20/2024
How to Talk About Politics at Work 3/20/2024
Novo Invests $556M in China Operations to Boost Manufacturing Capacity 3/20/2024
Italfarmaco Touts Positive Results in Phase III DMD Trial Ahead of PDUFA 3/20/2024
EU Parliament Endorses New Pharma Legislation, Provides More Market Protection for Companies 3/20/2024
Cautiously Stepping Into the Future of AI by Stepping Back Into the Past at DIA’s MASC 3/20/2024
With the Salary Growth Rate Slowing, Should Biopharma Employees Look for New Jobs? 3/20/2024
A new cancer treatment that uses a person’s own immune cells has been approved by the U.S. Food and Drug Administration (FDA) for treating the most dangerous type of skin cancer. Now this form of cellular therapy (tumor-infiltrating lymphocyte - or TIL therapy) is showing promise in advanced lung cancers through clinical trials underway at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).
AstraZeneca Buys Fusion in Potential $2B Deal, Joins Radiopharma Buying Spree 3/19/2024
Bayer’s Veozah Rival Hits Goals in Long-Term Phase III Hot Flash Study 3/19/2024
Engrail Raises $157M in Oversubscribed Series B to Move Neuro Pipeline Forward 3/19/2024
Crinetics Bags Second Phase III Win for Acromegaly, Heads for NDA Submission 3/19/2024
Orchard Wins FDA Approval for First Gene Therapy for Rare Pediatric Disease 3/19/2024
Bluebird Extends Cash Runway with $175M Financing to Support Gene Therapy Launch 3/19/2024
Regeneron Wins Appeal in Eylea-Lucentis Antitrust Case Against Novartis 3/19/2024
Report: 2024 U.S. Life Sciences Salary Trends 3/19/2024